<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(12)</volume><submitter>Kmiecik MJ</submitter><funding>Michael J. Fox Foundation for Parkinson's Research</funding><funding>Michael J. Fox Foundation for Parkinson&amp;apos;s Research</funding><pubmed_abstract>&lt;h4>Objective&lt;/h4>To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.&lt;h4>Methods&lt;/h4>We conducted a US-based observational case-control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases. The total cohort included 7,586,842 participants (n = 35,163 PD); 8791 LRRK2 p.G2019S carriers (565 with PD), 37,427 GBA1 p.N409S carriers (524 with PD), 244 dual LRRK2/GBA1 carriers (37 with PD), and 7.5 million noncarriers (34,037 with PD). PRS was calculated from the most recently published European genome-wide association study. Survival models estimated the cumulative incidence of PD. Logistic regressions estimated the relative odds of reporting motor and non-motor symptoms ac</pubmed_abstract><journal>Annals of clinical and translational neurology</journal><pagination>2482-2494</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12698958</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Genetic Modifiers of Parkinson's Disease: A Case-Control Study.</pubmed_title><pmcid>PMC12698958</pmcid><pubmed_authors>Fontanillas P</pubmed_authors><pubmed_authors>Norcliffe-Kaufmann L</pubmed_authors><pubmed_authors>Riboldi GM</pubmed_authors><pubmed_authors>Micheletti S</pubmed_authors><pubmed_authors>Hinds DA</pubmed_authors><pubmed_authors>Schneider RB</pubmed_authors><pubmed_authors>Stagaman K</pubmed_authors><pubmed_authors>23andMe Research Team</pubmed_authors><pubmed_authors>Holmes MV</pubmed_authors><pubmed_authors>Kmiecik MJ</pubmed_authors><pubmed_authors>Tat S</pubmed_authors><pubmed_authors>Guan A</pubmed_authors><pubmed_authors>Tung JY</pubmed_authors><pubmed_authors>Aslibekyan S</pubmed_authors><pubmed_authors>Shi J</pubmed_authors><pubmed_authors>Gottesman J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genetic Modifiers of Parkinson's Disease: A Case-Control Study.</name><description>&lt;h4>Objective&lt;/h4>To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.&lt;h4>Methods&lt;/h4>We conducted a US-based observational case-control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases. The total cohort included 7,586,842 participants (n = 35,163 PD); 8791 LRRK2 p.G2019S carriers (565 with PD), 37,427 GBA1 p.N409S carriers (524 with PD), 244 dual LRRK2/GBA1 carriers (37 with PD), and 7.5 million noncarriers (34,037 with PD). PRS was calculated from the most recently published European genome-wide association study. Survival models estimated the cumulative incidence of PD. Logistic regressions estimated the relative odds of reporting motor and non-motor symptoms ac</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T02:13:34.277Z</modification><creation>2026-05-24T03:12:32.537Z</creation></dates><accession>S-EPMC12698958</accession><cross_references><pubmed>40926580</pubmed><doi>10.1002/acn3.70176</doi></cross_references></HashMap>